Thorough quality control by European regulatory agencies and EPAR revision history

The European Medicines Agency (EMA) has approved the 28th post-authorization revision of the European Public Assessment Report (EPAR) for Aldurazyme (laronidase), a treatment for Mucopolysaccharidosis Type I (MPS I) developed by Sanofi and BioMarin Pharmaceutical. Since obtaining marketing authorization in June 2003 as the first enzyme replacement therapy (ERT) in Europe, it has consistently met regulatory compliance requirements through manufacturing process improvements and updates to the Summary of Product Characteristics (SmPC). This demonstrates that even 20 years after commercialization, as a mature biologic drug, it fully complies with the stringent safety monitoring requirements of health authorities. This has earned high trust from institutional investors by minimizing regulatory risks and ensuring long-term prescription stability.

Addressing unmet needs and the value of alpha-L-iduronidase enzyme replacement therapy

Aldurazyme directly supplements the alpha-L-iduronidase enzyme for patients with Hurler, Hurler-Scheie, and Scheie syndromes, where glycosaminoglycans (GAG) accumulate in the body due to genetic defects. It has provided a non-invasive weekly intravenous infusion option for severely ill patients who previously relied on hematopoietic stem cell transplantation (HSCT), significantly improving hepatomegaly and respiratory function. In particular, it has established itself as a standard of care (SoC) through its use in combination therapy for stabilizing systemic organ function before and after hematopoietic stem cell transplantation (HSCT). However, the inability to cross the blood-brain barrier (BBB) limits its efficacy in improving central nervous system (CNS) symptoms, which remains a challenge to overcome.

Commercialization Structure of the 50/50 Global Partnership Between BioMarin and Sanofi

The commercial success of Aldurazyme is underpinned by a 50/50 joint commercialization agreement between BioMarin and Sanofi Genzyme. BioMarin has established a revenue model in which it is solely responsible for the production of raw materials and finished drugs, while Sanofi handles global distribution and marketing, including in Europe, with net profits shared between them. For BioMarin, it functions as a stable source of revenue, ranging from $120 million to $130 million annually, generating robust cash flow. The partnership model between the two companies is cited as a representative case in which biotech drug technology is combined with the infrastructure of a global big pharma to maximize its commercial lifespan.

Competitive landscape and next-generation pipelines in the $3 billion Mucopolysaccharidosis market

The current global Mucopolysaccharidosis (MPS) treatment market is growing at an annual rate of over 8%, driven by the expansion of newborn screening (NBS), with a size of $3 billion to $3.3 billion annually. Aldurazyme serves as a cash cow based on its dominant market position, but faces challenges from BBB-permeable enzyme replacement therapies such as lepunafusp alfa (JR-171) that can penetrate the brain. Additionally, adeno-associated virus (AAV)-based gene therapies are being pursued in Phase 1/2 clinical trials with the goal of a one-time cure. Nevertheless, thanks to more than 20 years of accumulated long-term clinical safety data and its established pricing and reimbursement status, its short-term prescription exclusivity is expected to remain robust.